Publications
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
April 17, 2020
Journal of Biological Chemistry
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
March 25, 2020
Science Translational Medicine
Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Posters
April 2021
2021 Virtual American Academy of Neurology (AAN) Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): Interim Analysis Results
April 2021
American Association for Cancer Research (AACR) Annual Meeting 2021
Development of a Comprehensive Biomarker Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
March 2021
2021 MDA Virtual Clinical & Scientific Conference
Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Presentation)